2.
BIM基因多态性与EGFR-TKI治疗疗效的关系
Relationship between BIM gene polymorphism and therapeutic efficacy of tyrosine kinase inhibitor
| Therapeutic evaluation | BIM no polymorphism | BIM polymorphism | χ2 | P |
| CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; DCR: disease control rate. | ||||
| CR | 0 | 0 | 0 | 0 |
| PR | 33 | 3 | 2.746 | 0.098 |
| SD | 44 | 9 | 0.006 | 0.981 |
| PD | 25 | 9 | 2.931 | 0.087 |
| ORR | 32.4% | 14.3% | 2.746 | 0.098 |
| DCR | 75.5% | 57.1% | 2.931 | 0.087 |